Whole-Body Vibration Exercise in Patients With Parkinson's Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-75
SponsorIstanbul University

About this trial

This study is a prospective, single-blind, randomized controlled trial designed to investigate the effects of whole-body vibration (WBV) exercise on balance, mobility, fall risk, and proprioception in patients with Parkinson's disease.

A total of 68 patients diagnosed with Parkinson's disease, aged between 50 and 75 years, will be recruited from the outpatient clinic of the Department of Physical Medicine and Rehabilitation at Istanbul University, Istanbul Faculty of Medicine. Eligible participants will be clinically stable (no medication changes within the last 3 months), classified as Hoehn and Yahr stage 1-3, and MDS-UPDRS stage 2-3. Written informed consent will be obtained from all participants before enrollment.

Participants will be randomly assigned in a 1:1 ratio to either the intervention group (n=34) or the control group (n=34). Randomization will be performed using a computer-generated random allocation sequence. Outcome assessments will be conducted by a blinded assessor.

The intervention group will receive whole-body vibration (WBV) training in addition to a standardized home exercise program. WBV sessions will be performed using the Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Training will be conducted three times per week for 8 weeks (24 sessions total). Each session will include 5 sets of vibration exposure, consisting of 1 minute of vibration followed by 1 minute of rest. Exercises will be performed in semi-squat and lunge positions. Vibration parameters will be set at 6 Hz frequency with 2-4 mm amplitude. Sessions will be scheduled during the "on" phase of dopaminergic medication. Each session will include a 10-minute warm-up and a 5-minute cool-down period.

The control group will perform only the standardized home exercise program. Both groups will receive initial in-clinic instruction for the home exercise program, which includes posture exercises, breathing and relaxation exercises, lower extremity active range-of-motion exercises, stretching, quadriceps strengthening, terminal knee extension exercises, rhythmic gait training, and balance/coordination/proprioceptive exercises. Home exercises will be performed three times per week for 8 weeks, lasting 30-45 minutes per session. Participants will be contacted weekly to monitor adherence.

Outcome assessments will be conducted at baseline, at 8 weeks (post-intervention), and at 16 weeks (follow-up).

The primary outcome measure is the Berg Balance Scale (BBS).

Secondary outcome measures include:

* Timed Up and Go (TUG) test * Six-Minute Walk Test (6MWT) * Fall Risk Index measured by computerized static posturography (TETRAX®) * Knee joint position sense measured using an isokinetic dynamometer (Biodex System 3 Pro), calculated as absolute angular error

The primary analysis will evaluate changes in BBS scores between groups across time points using repeated measures analysis of variance. Secondary outcomes will be analyzed using similar statistical methods. Statistical significance will be set at p \< 0.05.

The study aims to determine whether WBV combined with a home exercise program provides superior improvements in balance, mobility, fall risk, and proprioception compared with a home exercise program alone in individuals with Parkinson's disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• Age between 50 and 75 years

Clinical diagnosis of Parkinson's disease

Hoehn and Yahr stage 1-3

MDS-UPDRS stage 2-3

Disqualifiers

• Participation in an inpatient or outpatient rehabilitation program within the last 3 months

Diagnosis of dementia or significant cognitive/communication impairment

Contraindications to whole-body vibration (e.g., severe peripheral neuropathy affecting vibration perception, epilepsy, pregnancy, metal implants or joint prostheses in the lower extremities, cardiac or brain pacemaker, uncontrolled hypertension, history of acute thrombosis)

Presence of additional neurological disorders affecting balance or neuromuscular performance

Trial design

Design model

Parallel

Treatments tested in this trial

  • Whole-Body Vibration Plus Home Exercise

    Device

    Participants in this arm will receive whole-body vibration (WBV) training in addition to a standardized home exercise program. WBV will be performed using the Power Plate pro5 platform, three times per week for 8 weeks (24 sessions). Each session will include 5 sets of 1-minute vibration with 1-minute rest intervals in semi-squat and lunge positions (6 Hz, 2-4 mm amplitude). Sessions will include a short warm-up and cool-down period. The home exercise program will consist of posture, breathing, stretching, strengthening, gait training, and balance/proprioceptive exercises, performed three times weekly for 8 weeks (30-45 minutes per session).

  • Home Exercise Only

    Other intervention

    Participants in this arm will receive a standardized home exercise program only. The program will include posture training, breathing and relaxation exercises, lower extremity active range-of-motion and stretching exercises, quadriceps strengthening, terminal knee extension exercises, rhythmic gait training, and balance/coordination/proprioceptive exercises. Participants will receive initial in-clinic instruction and written guidance. Exercises will be performed three times per week for 8 weeks, with each session lasting approximately 30-45 minutes. Participants will be contacted weekly to monitor adherence.

Treatment groups

68 Participants
are divided into 2 treatment groups
Group A: Whole-Body Vibration Plus Home ExerciseExperimental treatment 1 intervention
Group B: Home Exercise Program OnlyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Balance assessed by Berg Balance Scale (BBS)

Balance will be assessed using the Berg Balance Scale (BBS), a 14-item clinical scale that evaluates static and dynamic balance abilities. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 56. Higher scores indicate better balance performance.

Time frame
From baseline to 8 weeks (end of intervention)

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: